Skip to main content
SpringerLink
Log in

Comment on: “Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 24 September 2019

The Original Article was published on 13 July 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McGettigan P, Alonso Olmo C, Plueschke K, Castillon M, Nogueras Zondag D, Bahri P, et al. Patient Registries: an underused resource for medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf. 2019. https://doi.org/10.1007/s40264-019-00848-9 (Epub 13 Jul 2019).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. BMC Med Res Methodol. 2009;9:59. https://doi.org/10.1186/1471-2288-9-59.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Gliklich R, Dreyer N. Registries for evaluating patient outcomes: a user’s guide. Agency for Healthcare Research and Quality; 2007.

  4. Zaletel M, Kralj M. Methodological guidelines and recommendations for efficient and rational governance of patient registries. PARENT. 2015;25:232.

    Google Scholar 

  5. European Medicines Agency. Patient Registries. http://www.ema.europa.eu/ema/index.jsp%3fcurl%3dpages/regulation/general/general_content_000658.jsp%26mid%3dWC0b01ac0580961211. Accessed 12 Aug 2019.

  6. REGULATION (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC 2014. https://ec.europa.eu/health/human-use/clinical-trials/regulation_en. Accessed 12 Aug 2019

  7. NIHR. National Institute for Health Research Glossary. https://www.nihr.ac.uk/about-us/glossary.htm. Accessed 12 Aug 2019

  8. Clinical Trials.gov Glossary n.d.

  9. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case–control studies. Emerg Med J. 2003;20:54. https://doi.org/10.1136/emj.20.1.54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medialis Ltd, Oxford, UK

    Ravi Jandhyala

Authors
  1. Ravi Jandhyala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ravi Jandhyala.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this letter.

Conflict of interest

Ravi Jandhyala is the managing director of Medialis Ltd, a Medical Affairs consultancy that offers consultation on clinical research as a paid service.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jandhyala, R. Comment on: “Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments”. Drug Saf 42, 1515–1516 (2019). https://doi.org/10.1007/s40264-019-00862-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-019-00862-x

Search

Navigation